Hyaluronic acid containing compositions for treatment of wounds, scars, post-surgical adhesion formation

Abstract

Pharmaceutical compositions are provided for enhancing the therapeutic effect of biologically active peptides, especially peptides derived from human lactoferrin. The compositions are useful for the treatment and/or prevention of wounds, scars, and post surgical adhesions.

1 . A pharmaceutical composition comprising:
 i) one or more biologically active peptides comprising the amino acid sequence Phe-X1-X2-X3-X4-X5-X6-X7-Lys-Val-Arg (SEQ ID NO:1),   wherein amino acid X1 is Gln or Ala, amino acid X2 is Trp or Leu, amino acid X3 is Gln, Ala, Orn, Nle or Lys, amino acid X4 is Arg, Ala or Lys, amino acid X5 is Asn, Ala, Orn or Nle, amino acid X6 is Met, Ala or Leu, amino acid X7 is Arg, Ala or Lys, and   ii) a high molecular weight hyaluronic acid or a pharmaceutical acceptable salt of a high molecular weight hyaluronic acid.   
     
     
         2 . The pharmaceutical composition according to  claim 1 , wherein the biologically active peptide is a peptide comprising the amino acid sequence SEQ ID NO:4. 
     
     
         3 . The pharmaceutical composition according to  claim 2 , wherein the biologically active peptide is a cyclic peptide where the two cysteines form a cysteine bridge comprising the amino acid sequence SEQ ID NO:56. 
     
     
         4 . The pharmaceutical composition according to  claim 1 , wherein the biologically active peptide is a peptide comprising of the amino acid sequence SEQ ID NO:50. 
     
     
         5 . The pharmaceutical composition according to  claim 1 , wherein the high molecular weight hyaluronic acid has an average molecular weight higher than 300,000 Da. 
     
     
         6 . The pharmaceutical composition according to  claim 1 , wherein the peptide is present at a concentration of between 0.1 mg/ml and 100 mg/ml. 
     
     
         7 . The pharmaceutical composition according to  claim 1 , wherein the hyaluronic acid is present at a concentration of between 0.1 and 10% (w/w). 
     
     
         8 . (canceled) 
     
     
         9 . (canceled) 
     
     
         10 . A method for the prevention of the formation of post surgical scars, adhesions, and keloids in connection with surgical procedures comprising the administration of a pharmaceutical composition according to  claim 1  to a subject in need such treatment. 
     
     
         11 . The pharmaceutical composition according to  claim 2 , wherein the high molecular weight hyaluronic acid has an average molecular weight higher than 300,000 Da. 
     
     
         12 . The pharmaceutical composition according to  claim 3 , wherein the high molecular weight hyaluronic acid has an average molecular weight higher than 300,000 Da. 
     
     
         13 . The pharmaceutical composition according to  claim 4 , wherein the high molecular weight hyaluronic acid has an average molecular weight higher than 300,000 Da. 
     
     
         14 . The pharmaceutical composition according to  claim 1 , wherein the high molecular weight hyaluronic acid has an average molecular weight higher than 800,000 Da. 
     
     
         15 . The pharmaceutical composition according to  claim 2 , wherein the high molecular weight hyaluronic acid has an average molecular weight higher than 800,000 Da. 
     
     
         16 . The pharmaceutical composition according to  claim 3 , wherein the high molecular weight hyaluronic acid has an average molecular weight higher than 800,000 Da. 
     
     
         17 . The pharmaceutical composition according to  claim 4 , wherein the high molecular weight hyaluronic acid has an average molecular weight higher than 800,000 Da. 
     
     
         18 . The pharmaceutical composition according to  claim 1 , wherein the peptide is present at a concentration of between 0.5 mg/ml and 25 mg/ml. 
     
     
         19 . The pharmaceutical composition according to  claim 1 , wherein the hyaluronic acid is present at a concentration of between 0.5 and 2.5% (w/w). 
     
     
         20 . A method for the prevention of the formation of post surgical scars, adhesions, and keloids in connection with surgical procedures comprising the administration of a pharmaceutical composition according to  claim 2  to a subject in need such treatment. 
     
     
         21 . A method for the prevention of the formation of post surgical scars, adhesions, and keloids in connection with surgical procedures comprising the administration of a pharmaceutical composition according to  claim 3  to a subject in need such treatment. 
     
     
         22 . A method for the prevention of the formation of post surgical scars, adhesions, and keloids in connection with surgical procedures comprising the administration of a pharmaceutical composition according to  claim 4  to a subject in need such treatment.